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ABSTRACT
Objective: To assess whether the association between reperfusion and improved clinical out-
comes after stroke differs depending on the site of the arterial occlusive lesion (AOL).
Methods: We pooled data from Solitaire With the Intention for Thrombectomy (SWIFT), Solitaire
FR Thrombectomy for Acute Revascularisation (STAR), Diffusion and Perfusion Imaging Evalua-
tion for Understanding Stroke Evolution Study 2 (DEFUSE 2), and Interventional Management
of Stroke Trial (IMS III) to compare the strength of the associations between reperfusion and clin-
ical outcomes in patients with internal carotid artery (ICA), proximal middle cerebral artery (MCA)
(M1), and distal MCA (M2/3/4) occlusions.
Results: Among 710 included patients, the site of the AOL was the ICA in 161, the proximal MCA in
389, and the distal MCA in 160 patients (M2 5 131, M3 5 23, and M4 5 6). Reperfusion was
associated with an increase in the rate of good functional outcome (modified Rankin Scale [mRS]
score 0–2) in patients with ICA (odds ratio [OR] 3.5, 95% confidence interval [CI] 1.7–7.2) and
proximalMCA occlusions (OR6.2, 95%CI 3.8–10.2), but not in patientswith distal MCA occlusions
(OR 1.4, 95% CI 0.8–2.6). Among patients with M2 occlusions, a subset of the distal MCA cohort,
reperfusion was associated with excellent functional outcome (mRS 0–1; OR 2.2, 95%CI 1.0–4.7).
Conclusions: The association between endovascular reperfusion and better clinical outcomes is
more profound in patients with ICA and proximal MCA occlusions compared to patients with distal
MCA occlusions. Because there are limited data from randomized controlled trials on the effect of
endovascular therapy in patients with distal MCA occlusions, these results underscore the need
for inclusion of this subgroup in future endovascular therapy trials. Neurology® 2016;86:762–770
GLOSSARY
AOL 5 arterial occlusive lesion; CI 5 confidence interval; DEFUSE 2 5 Diffusion and Perfusion Imaging Evaluation for
Understanding Stroke Evolution Study 2; ICA 5 internal carotid artery; IMS III5 Interventional Management of Stroke Trial;
M1 5 proximal middle cerebral artery; M2/3/4 5 distal middle cerebral artery; MCA 5 middle cerebral artery; MERCI 5
Mechanical Embolus Removal in Cerebral Ischemia; MR 5 magnetic resonance; mRS 5 modified Rankin Scale; mTICI 5
modified Thrombolysis in Cerebral Infarction; NIHSS 5 NIH Stroke Scale; OR 5 odds ratio; sICH 5 symptomatic intracranial
hemorrhage; STAR 5 Solitaire FR Thrombectomy for Acute Revascularisation; SWIFT 5 Solitaire With the Intention for
Thrombectomy; tPA 5 tissue plasminogen activator.
Reperfusion is associated with improved outcomes in acute ischemic stroke,1 but it is not known
if the response to endovascular reperfusion differs depending on the site of the arterial occlusive
lesion (AOL). A modifying role of the site of AOL on the clinical effect of reperfusion could
potentially impact clinical trial design in terms of patient selection criteria and sample size
calculations. The results of prior studies that have examined the effect of the site of the arterial
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occlusion (internal carotid artery [ICA] vs
proximal middle cerebral artery [MCA]) on
the association between endovascular reperfu-
sion and clinical outcome have been inconclu-
sive.2–5 Some studies suggest that there may be
less benefit from reperfusion in patients with
ICA occlusions.2,4,5 In a pooled analysis of the
Mechanical Embolus Removal in Cerebral
Ischemia (MERCI) and Multi-MERCI stud-
ies, ICA occlusion was associated with an
approximate 2-fold increased chance of mor-
tality after adjusting for reperfusion, baseline
NIH Stroke Scale (NIHSS) score, and age.4
Second, a large (n . 600) prospective study
showed that patients with proximal occlusions
had worse clinical outcomes despite higher re-
perfusion rates compared to patients with
more peripheral occlusions.2 Third, in a sys-
tematic review of endovascular therapy, pa-
tients with ICA occlusions had worse
outcomes compared to patients with more
peripheral occlusions.5 The Diffusion and Per-
fusion Imaging Evaluation for Understanding
Stroke Evolution Study 2 (DEFUSE 2), a pro-
spective cohort of ischemic stroke patients
who underwent a baseline MRI scan before
endovascular therapy, also showed worse out-
comes in patients with ICA occlusions, but
this association was driven by a high rate of
poor outcomes in patients with ICA occlu-
sions who did not reperfuse. An assessment
of the response to reperfusion suggested that
patients with ICA occlusions benefitted more
from reperfusion than patients with MCA
occlusions.3
In this study, we used pooled individual
patient data from 4 large endovascular trials
to investigate whether the effect of endovascu-
lar reperfusion on clinical outcomes differs de-
pending on the site of the AOL. This pooled
data analysis provides us with sufficient power
to compare the response to endovascular re-
perfusion between patients with ICA, proxi-
mal MCA (M1), and more distal MCA
(M2/3/4) occlusions.
METHODS Study design and procedures. Criteria for
inclusion in this pooled analysis were as follows: prospective clin-
ical studies with more than 100 endovascularly treated patients,
blinded outcome assessment, and determination of AOL and re-
perfusion status on angiography by core laboratory reading. A
PubMed search identified 8 studies that fulfilled these
criteria.2,4,6–12 Corresponding authors from all studies were con-
tacted with a request for participation and 4 agreed: Interven-
tional Management of Stroke Trial (IMS III), Solitaire With the
Intention for Thrombectomy (SWIFT), Solitaire FR Throm-
bectomy for Acute Revascularisation (STAR), and DEFUSE 2.
The full methodology of the 4 studies has been described pre-
viously.8–11 In brief, SWIFT was a randomized trial comparing
the efficacy and safety of Solitaire with the MERCI Retrieval
System.10 STAR was a prospective single-arm study of patients
who received the Solitaire retrievable stent device.12 DEFUSE 2
was a prospective cohort of ischemic stroke patients who
underwent a baseline MRI scan before endovascular therapy.8
From IMS III, a randomized trial assigning patients to IV
thrombolysis alone vs IV thrombolysis with additional
endovascular treatment, only patients who underwent
endovascular therapy and had evidence of a large artery
occlusion on angiography were included.11 Patients with
extensive early infarct signs on the baseline CT or magnetic
resonance (MR) scan (CT showing hypodensity or MR
showing hyperintensity involving greater than 1/3 of the
MCA territory) were excluded from the IMS III, STAR, and
SWIFT studies, to limit the rate of futile reperfusion.13
Similarly, patients with extensive early infarct signs on
baseline MRI or CT were generally not offered endovascular
treatment at the DEFUSE 2 study sites and were thus excluded
from enrollment.
Baseline stroke severity was assessed with the NIHSS by a
certified investigator. Functional outcome was assessed at day
90 with the modified Rankin Scale (mRS). Good functional
outcome was defined as an mRS score of 0–2 and excellent
functional outcome as mRS 0–1. Clinical endpoints at 90 days
were assessed by investigators masked to the patients’ baseline
clinical and radiographic data. For each study, blinded investi-
gators at core imaging laboratories reviewed cerebral angiogra-
phy studies and were masked to clinical data. Angiograms were
evaluated for reperfusion status by using the modified Throm-
bolysis in Cerebral Infarction (mTICI) rating scale.11 Sympto-
matic intracranial hemorrhage (sICH) in the present study was
defined as originally reported in each study. In DEFUSE 2, this
was defined according to the definition in the Safe Implemen-
tation of Thrombolysis in Stroke Monitoring Study 2 (SITS
MOST).14 SWIFT defined sICH as any parenchymal hema-
toma, subarachnoid hemorrhage, or intraventricular hemor-
rhage associated with a worsening of the NIHSS score by 4 or
more within 24 hours. In STAR, sICH was scored according to
the European Cooperative Acute Stroke Study trial definition.12
The definition in IMS III was an intracranial hemorrhage tem-
porally related to a decline in neurologic status in the judgment
of the clinical investigator.11
Standard protocol approvals, registrations, and patient
consents. Approval for the study was obtained from local insti-
tutional review boards. Written informed consent was provided
by all patients or a legally authorized representative. Included
studies in this analysis have been registered previously: DEFUSE
2 NCT01327989, IMS III NCT00359424, STAR
NCT01327989, and SWIFT NCT01054560.
Statistical analysis. In the primary analysis, final mTICI scores
were dichotomized and defined as substantial reperfusion (mTI-
CI 2B–3) vs no substantial reperfusion (mTICI 0–1–2A). Regres-
sion analyses were performed to compare the strength of the
associations between reperfusion and good functional outcome
(mRS 0–2) in patients with ICA, M1, and M2/3/4 occlusions.
Including more distal lesions (M3 and M4) in the distal MCA
group could obscure a potential beneficial effect of reperfusion on
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clinical outcomes in patients with an occlusion of the M2. We
therefore assessed the association between reperfusion and the
primary and secondary outcomes separately in the subgroup of
patients with an M2 obstruction. To assess the associations, a
multivariate logistic regression model was created with good func-
tional outcome as the dependent variable. The primary aim was
to determine if the interaction between reperfusion and site of the
AOL is an independent predictor in this model.
The base model included age, baseline NIHSS, AOL, reper-
fusion, and the 2-way interaction of AOL and reperfusion. Dur-
ing the preliminary variable selection, time to treatment, diabetes,
history of stroke, and prior treatment with tissue plasminogen
activator (tPA) were added, one at a time, to the base model. Var-
iables that were significant at an a #0.10 were considered can-
didates for the final model. For the final model, variables were
added sequentially starting with the variable with the lowest
p value from the group of candidate predictors. We retained
variables with p values #0.05 in the final model. All qualifying
variables from the preliminary selection phase were considered
along with their 2-way interaction with site of AOL.
We prespecified several secondary analyses based on different
endpoints: (1) excellent functional outcome, defined as an mRS
score 0–1 at day 90; (2) mortality at day 90; and (3) sICH. In
a tertiary analysis, we used the full range of the mRS as the
dependent variable. We compared the mRS distribution, divided
into 6 categories (0, 1, 2, 3, 4, 5–6), between patients with and
without reperfusion using ordinal logistic regression. The
adjusted ordinal logistic regression was stratified according to
age (dichotomized based on median age of all subjects), NIHSS
(dichotomized based on median NIHSS of all subjects), and any
other variable identified in the primary analysis. Finally, we con-
ducted an exploratory analysis that was identical to the primary
analysis but with reperfusion as an ordinal predictor variable,
divided into 4 categories: 0–1, 2A, 2B, 3, instead of a dichoto-
mous variable (mTICI 0–2A vs 2B–3).
RESULTS Data on 787 patients from IMS III,
STAR, SWIFT, and DEFUSE 2 were pooled.
Seventy-seven patients were excluded from the
analysis because details on functional outcome,
reperfusion, or AOL status were missing (figure e-1
on the Neurology® Web site at Neurology.org).
Characteristics of the remaining 710 patients are
reported in table 1. Differences in the baseline
characteristics between studies reflect the differences
Table 1 Characteristics of studies included in the pooled analysis
DEFUSE 2
(n 5 99)
IMS IIIa
(n 5 312)
STAR
(n 5 185)
SWIFT
(n 5 114)
All
(n 5 710)
Year of publication/age,
y, mean (SD)
2012/64.8 (16.1) 2013/65.8 (12.6) 2013/68.5 (12.4) 2012/67.9 (10.9) 66.7 (12.9)
Male sex, n (%) NIHSS 49 (49) 150 (48) 73 (39) 56 (49) 328 (46)
Median 16 18 17 18 17
IQR 11–20 14–21 13–20 14–20 13–20
Prestroke mRS
Median (range) 0 (0–4) 0 (0–2) 0 (0–2) 0 (0–5) 0 (0–5)
2 or better, % 97 100 100 94 99
Medical history, %
Diabetes mellitus 18 21 13 27 18
Prior stroke 14 11 14 19 12
IV thrombolysis 53 100 58 45 74
Site of occlusion, n (%)
ICA 29 (29) 73 (23) 34 (18) 25 (22) 161 (23)
Proximal MCA 58 (59) 133 (43) 127 (69) 71 (62) 389 (55)
Distal MCA 12 (12) 106 (34) 24 (13) 18 (16) 160 (23)
M2 8 (8) 81 (26) 24 (13) 18 (16) 131 (19)
M3 4 (4) 19 (6) 0 (0) 0 (0) 23 (3)
M4 0 (0) 6 (2) 0 (0) 0 (0) 6 (1)
Onset to start of therapy, min
Median 348 248 249 301 260
IQR 270–470 210–284 181–312 247–375 215–318
Reperfusion,b n (%) 46 (47) 124 (40) 164 (89) 79 (69) 413 (58)
Abbreviations: DEFUSE 2 5 Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study 2;
ICA5 internal carotid artery; IMS III5 Interventional Management of Stroke Trial; IQR5 interquartile range; MCA5middle
cerebral artery; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; STAR 5 Solitaire FR Thrombectomy for Acute
Revascularisation; SWIFT 5 Solitaire With the Intention for Thrombectomy.
aOnly the IV 1 intra-arterial treatment arm of the IMS III trial is included in this pooled analysis.
bModified Thrombolysis in Cerebral Infarction Scale $2B.
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in study design between studies, e.g., in IMS III all
patients received IV tPA before endovascular therapy
and in DEFUSE 2 the time window for treatment
was longer than in the other studies. Baseline
characteristics were well-matched between patients
who did and who did not achieve endovascular
reperfusion (mTICI 2B–3), except for a higher rate
of IV tPA in patients who did not reperfuse (83%)
than in patients with reperfusion (67%). This
imbalance is explained by 2 characteristics of the
IMS III trial. Patients who underwent endovascular
therapy in IMS III had lower rates of reperfusion
(40%) and a higher rate of IV tPA use (100%,
because treatment with IV tPA was a prerequisite
for inclusion) compared to patients from the other
trials. Consequently, the observation of a higher
rate of IV tPA use in patients who did not reperfuse
(tables 1 and 2) is most likely due to confounding by
IMS III. The site of the AOL was the ICA in 161, the
proximal MCA in 389, and the distal MCA in 160
(M2 5 131, M3 5 23, and M4 5 6) patients. The
distribution of postprocedure mTICI scores, stratified
by AOL, is shown in figure e-2.
Reperfusion was associated with an increased rate
of good functional outcome (mRS 0–2) in the overall
population (odds ratio [OR] 3.4, 95% confidence
interval [CI] 2.5–4.7), but there was a differential
response to reperfusion according to AOL; the asso-
ciation between reperfusion and good functional out-
come was stronger in patients with ICA and proximal
MCA occlusions compared to patients with distal
MCA occlusions (p 5 0.001 for the difference in
ORs between ICA and proximal MCA vs distal
MCA occlusions; table 3 and figure 1). Age, baseline
NIHSS, and time to treatment were additional pre-
dictors of good functional outcome, but adjusting for
these variables had little influence on the association
between reperfusion and good functional outcome,
which remained stronger for patients with ICA and
proximal MCA vs distal MCA occlusions (p for
adjusted difference in ORs is 0.003; table 3 and figure
e-2). Limiting the distal MCA cohort to patients with
M2 occlusions (i.e., excluding patients with M3 and
M4 lesions) also did not alter the results (table 3 and
figure 1).
The effects of reperfusion on the secondary out-
comes (excellent functional outcome, mortality, and
sICH) are reported in table 3, figure 1, and figure
e-3. The association between reperfusion and excel-
lent functional outcome was significant in patients
with ICA and proximal MCA occlusions but not in
patients with distal MCA occlusions (p 5 0.003 for
the difference in ORs between ICA and proximal
MCA vs distal MCA). When the distal MCA cohort
was limited to patients with M2 occlusions, the asso-
ciation between reperfusion and excellent functional
outcome was, however, also present in this group
(p 5 0.04). The amount of patients with M3/4 oc-
clusions was too small, 29 patients, to draw any con-
clusions (figure e-4). Mortality was reduced with
reperfusion in the overall cohort. This association
was driven by fewer deaths with reperfusion among
patients with ICA and proximal MCA occlusions but
not among patients with distal MCA occlusions (p5
0.01 for the difference between the ORs for ICA and
proximal MCA vs distal MCA). sICH was reduced
with reperfusion in the overall cohort, and there was
no interaction between the site of AOL and the asso-
ciation between reperfusion and sICH (p 5 0.5).
In a tertiary analysis, we assessed the effect of re-
perfusion on the distribution of mRS scores at day
90, stratified by AOL. Reperfusion was associated
with better functional outcome when analyzed over
the full distribution of mRS scores in patients with
ICA occlusions (OR 2.9; 95% CI 1.6–5.2) and prox-
imal MCA occlusions (OR 5.0; 95% CI 3.3–7.4),
but not in patients with distal MCA occlusions
(OR 1.2; 95% CI 0.7–2.1) (figure 2). We identified
an interaction between reperfusion status and site of
AOL (ICA and proximal MCA vs distal MCA; p ,
0.001). This result was unaltered after adjusting for
baseline predictors of outcome (figure e-5). The
Table 2 Baseline characteristics stratified by
reperfusion status
Reperfusion
(n 5 413;
58%)
No
reperfusion
(n 5 297;
42%)
Age, y, mean (SD) 66.9 (12.7) 66.4 (13.2)
Male sex, n (%) 178 (43) 150 (51)
NIHSS
Median 17 17
IQR 13–20 14–21
IV thrombolysis, n (%) 277 (67) 246 (83)
Onset to start of
endovascular
therapy, min
Median 259 264
IQR 212–322 221–316
Site of occlusion, n (%)
ICA 87 (21) 74 (25)
Proximal MCA 251 (61) 138 (47)
Distal MCA 75 (18) 85 (29)
M2 branch 67 (16) 64 (22)
M3 branch 6 (1) 17 (6)
M4 branch 2 (1) 4 (1)
Abbreviations: ICA 5 internal carotid artery; IQR 5 inter-
quartile range; MCA 5middle cerebral artery; NIHSS 5 NIH
Stroke Scale.
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results were also unaltered when the distal MCA
cohort was limited to patients with M2 occlusions.
In an exploratory analysis, the association between
reperfusion and good functional outcome was as-
sessed using the full range of the mTICI scale (i.e.,
4 categories: 0–1, 2A, 2B, and 3; figure e-6). Based
on this analysis, a 1-point increase in mTICI category
was associated with an OR of 2.0 (95% CI 1.4–2.9)
for good functional outcome in patients with ICA
occlusions and an OR of 2.2 (95% CI 1.8–2.8) for
proximal MCA occlusions. These associations re-
mained present after adjusting for baseline predictors.
The linear assumption between reperfusion, assessed
as an ordinal variable, and good functional outcome
was not met in patients with distal MCA occlusions
(figure e-6).
DISCUSSION In this pooled analysis of stroke pa-
tients who underwent acute endovascular treatment,
reperfusion was associated with an increased chance
of good and excellent functional outcome. This effect
was strongest in patients with ICA and proximal
MCA occlusions and less pronounced in patients
with more distal MCA lesions (i.e., occlusions of
the second or more distal branch of the MCA).
The chosen clinical endpoint may influence the
ability to demonstrate a benefit of reperfusion in pa-
tients with distal MCA occlusions. In patients with
M2 occlusions, reperfusion was not associated with
good functional outcome (mRS 0–2), but it was
associated with excellent functional outcome (mRS
0–1). When the 131 patients with M2 lesions were
pooled with the 29 patients with M3/4 lesions, nei-
ther association was significant, supporting the
hypothesis that the natural history in the most distal
lesions may be so favorable that there is little room to
demonstrate improved outcomes with reperfusion
even when excellent clinical outcome is the end-
point.15 Our pooled analysis has a very small sample
of patients with M3/4 occlusions, hampering
Table 3 Effect of reperfusion on clinical outcomes in pooled analysis of endovascularly treated patients
Overall
(n 5 710)
ICA
(n 5 161)
Middle cerebral artery
p Value for
interactiona
Proximal (M1)
(n 5 389)
Distal (M2/3/4)
(n 5 160)
M2
(n 5 131)
Good functional outcome (mRS 0–2)
No. (%) with reperfusion 224 (54) 39 (45) 145 (58) 40 (53) 34 (51)
No. (%) without reperfusion 72 (26) 14 (19) 25 (18) 38 (45) 26 (41)
RR (95% CI) 2.1 (1.7–2.6) 2.4 (1.4–4.0) 3.2 (2.2–4.6) 1.2 (0.9–1.6) 1.2 (0.9–1.8)
OR (95% CI) 3.4 (2.5–4.7) 3.5 (1.7–7.2) 6.2 (3.8–10.2) 1.4 (0.8–2.6) 1.5 (0.8–3.0) 0.001
OR (95% CI) adjustedb 4.3 (2.9–6.2) 5.2 (2.2–12.5) 6.9 (3.9–12.0) 2.2 (1.0–4.7)c 2.1 (0.9–4.9) 0.003
Excellent functional outcome (mRS 0–1)
No. (%) with reperfusion 164 (40) 23 (26) 111 (44) 30 (40) 27 (40)
No. (%) without reperfusion 48 (16) 9 (12) 14 (10) 25 (29) 15 (23)
OR (95% CI) 3.4 (2.4–4.9) 2.6 (1.1–6.0) 7.0 (3.8–12.9) 1.6 (0.8–3.1) 2.2 (1.0–4.7) 0.003
OR (95% CI) adjustedb 4.1 (2.7–6.2) 3.1 (1.2–7.9) 7.6 (3.9–14.8) 2.3 (1.0–5.4)c 3.0 (1.1–7.8) 0.01
Mortality
No. (%) with reperfusion 52 (13) 16 (18) 25 (10) 11 (15) 9 (13)
No. (%) without reperfusion 83 (28) 29 (39) 41 (30) 13 (15) 11 (17)
OR (95% CI) 0.4 (0.3–0.5) 0.3 (0.1–0.7) 0.2 (0.1–0.4) 0.9 (0.3–2.2) 0.7 (0.3–1.9) 0.01
OR (95% CI) adjustedb 0.3 (0.2–0.5) 0.4 (0.2–0.7) 0.3 (0.2–0.5) 1.0 (0.4–2.3) 0.8 (0.3–2.2) 0.03
Symptomatic intracranial hemorrhage
No. (%) with reperfusion 14 (3) 5 (6) 6 (2) 3 (4) 3 (5)
No. (%) without reperfusion 30 (10) 9 (12) 14 (10) 7 (8) 6 (9)
OR (95% CI) 0.3 (0.2–0.6) 0.4 (0.1–1.4) 0.2 (0.1–0.6) 0.5 (0.1–1.9) 0.5 (0.1–1.9) 0.5
OR (95% CI) adjustedb 0.3 (0.2–0.6) 0.6 (0.2–2.1) 0.2 (0.1–0.5) 0.5 (0.1–2.3) 0.5 (0.1–2.6) 0.5
Abbreviations: CI 5 confidence interval; ICA 5internal carotid artery; MCA 5 middle cerebral artery; mRS 5 modified Rankin Scale; OR 5 odds ratio; RR 5
relative risk.
ap Value for interaction between reperfusion and arterial occlusive lesion (ICA/proximal MCA vs distal MCA).
bAdjusted for age, baseline NIH Stroke Scale score, and time to treatment.
cp 5 0.06.
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conclusions to be drawn about reperfusion and clin-
ical outcomes in this subgroup.
Data on the association between reperfusion and
good functional outcome in patients with M2 occlu-
sions following endovascular treatment have been
inconclusive.16–19 These differing results may be due
to variations in the population of patients who were
included. Additionally, among patients with M2 oc-
clusions, there may be variability in the association
between reperfusion and favorable clinical outcome as
a result of variable interpretations of what constitutes
an M1 vs an M2 occlusion. Differences between stud-
ies in the definition of M1 vs M2 occlusions might
have influenced our pooled study since we relied on
the AOL ratings of the original studies. Due to a
restrictive definition of M1 occlusions in IMS III, it
is likely that some lesions were rated as M1 occlusions
in the DEFUSE 2, STAR, and SWIFT studies, but as
M2 occlusions in IMS III. Consequently, we might
have found an even stronger interaction between re-
perfusion and site of AOL (ICA and proximal MCA
vs distal MCA) if a uniform definition had been
applied in all studies.
Because there is a paucity of data from randomized
controlled trials on patients with distal MCA
occlusions, we could only investigate the effect of
reperfusion, and not the effect of endovascular treat-
ment, in relation to the site of the AOL. The results
should be interpreted in this context. They indicate
that the association between reperfusion and good
clinical outcomes is stronger in patients with proximal
occlusions compared to distal occlusions. Patients
with distal MCA occlusions might experience less
benefit from reperfusion because they have less brain
tissue at risk of infarction (i.e., less brain tissue that
can be salvaged with reperfusion) compared to pa-
tients with more proximal MCA or ICA occlusions.
This finding may be useful in the design of future tri-
als, specifically for the estimation of the expected
effect size. Our results, however, do not indicate that
patients with distal MCA occlusions do not benefit
from endovascular therapy. Patients with distal
MCA occlusions should, therefore, not be excluded
from endovascular therapy or from future trials of en-
dovascular therapy based on the results of this study.
In contrast, the results underscore the need for addi-
tional clinical trial data to determine the effect of en-
dovascular therapy in this subgroup.
We also assessed the effect of reperfusion on
sICH. A large meta-analysis, including patients who
received IV thrombolysis, endovascular therapy, or
no active treatment, did not show an association
Figure 1 Associations between reperfusion and clinical outcomes stratified by arterial occlusive lesion
Graphs show the odds ratios for the associations between reperfusion and good functional outcome defined as modified
Rankin Scale (mRS) score of 0–2 (A), excellent functional outcome defined as mRS of 0–1 (B), mortality (C), and symptomatic
intracranial hemorrhage (D). Effects are shown separately for patients with internal carotid artery (ICA), proximal middle
cerebral artery (MCA), distal MCA, and M2 occlusions. Corresponding odds ratios and their 95% confidence intervals are
listed in table 3.
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between recanalization and sICH.1 Here we report
reduced sICH rates in patients with reperfusion fol-
lowing endovascular therapy. We acknowledge that
determining the association between reperfusion and
sICH has been confounded by the various definitions
of sICH used across trials. Therefore, these findings
would need to be confirmed in other cohorts, ideally
using a more uniform definition of sICH.
This study has some limitations. Data were pooled
from several studies with variations in design, which
introduces variability in the analysis. The variation
in time to treatment between the various studies
could potentially have influenced the results.
However, adjusting the analyses for time to treatment
and other baseline predictors of outcome did not alter
the results. The association between reperfusion and
outcome was studied in patients treated with a wide
variety of intra-arterial therapies. Although there is
no evidence that the response to reperfusion differed
depending on the method of endovascular treatment
used, this cannot be excluded. As reported above,
another factor, which could have influenced the re-
sults, is the variability in the definition of M1 and
M2 lesions in the various studies. Variability between
studies in the way core laboratories defined mTICI
scores may also have affected our results. Importantly,
Figure 2 Distribution of 90-day functional outcome according to the modified Rankin Scale (mRS) stratified
by reperfusion status and arterial occlusive lesion (AOL)
The graphs show the distribution of 90-day functional outcomes according to the mRS score stratified by reperfusion sta-
tus and AOL (internal carotid artery [ICA], proximal middle cerebral artery [MCA], and distal MCA occlusions). Reperfusion is
associated with better functional outcomes, assessed using the full distribution of mRS scores, in patients with ICA (odds
ratio [OR] 2.9; 95% confidence interval [CI] 1.6–5.2) and proximal MCA occlusions (OR 5.0; 95% CI 3.3–7.4), but not in
patients with distal MCA occlusions (OR 1.2; 95% CI 0.7–2.1).
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it is unlikely that any variability in angiographic as-
sessments would have systematically biased the results
of our analyses. Another limitation is that we were
merely able to adjust the results for predictors of out-
come that were assessed in all studies. Predictive varia-
bles that were only collected in selected trials, such as
MRI or computed tomography perfusion mismatch
pattern and the Alberta Stroke Program Early CT
Score (ASPECTS), could therefore not be taken into
account.8,20 Finally, it would have been of interest to
study the association between reperfusion and clinical
outcomes in more detailed subgroups. For example, we
were unable to compare proximal vs distal ICA lesions,
because this classification was unavailable.
Our findings from a large pooled data analysis of
acute stroke patients enrolled in prospective endovas-
cular stroke studies suggest that there is a differential
response to reperfusion based on site of AOL. Specif-
ically, the beneficial effect of endovascular reperfusion
is more pronounced for patients with proximal (ICA
and proximal MCA) occlusions than for patients with
more distal MCA occlusions.
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